TITLE

Roche files saquinavir NDA

PUB. DATE
September 1995
SOURCE
Drug Topics;9/18/95, Vol. 139 Issue 18, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on Hoffman-LaRoche's submission of a new drug application for Invirase or saquinavir, a protease inhibitor used in the treatment of AIDS.
ACCESSION #
9510075892

 

Related Articles

  • From the Archives of The Advocate. Romesburg, Don // Advocate;05/23/2000, Issue 812, p22 

    Reports on the use of protease inhibitors to treat AIDS. Side effects; Complications of patients whose lives have been extended by treatment; Coverage of the development by `Advocate' magazine.

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • Factors Associated with Poor Immunologic Responses Despite Viral Suppression in Markedly Immunosuppressed Patients. Collazos, Julio; Asensi, Víctor; Cartón, José Antonio // AIDS Patient Care & STDs;Jun2007, Vol. 21 Issue 6, p378 

    To determine the factors associated with poor immunologic responses despite viral suppression in markedly immunocompromised patients (≤200 CD4 cells per microliter at baseline), individuals with less than 100 CD4 increases after 12 months of nelfinavir-based highly active antiretroviral...

  • Diabetes, protease-inhibitor link unproved: directorate.  // CMAJ: Canadian Medical Association Journal;09/01/97, Vol. 157 Issue 5, p502 

    States that the Therapeutic Drugs Directorate at Health Canada find no conclusive evidence to support a causal relationship between protease inhibitors and diabetes or hyperglycemia in HIV-infected patients.

  • Pharmacy care Kit available from Roche.  // Drug Topics;10/10/94, Vol. 138 Issue 19, p8 

    Reports on the availability of a pharmacy counseling service from Roche Laboratories for patients on Roferon-A therapy.

  • Toradol labeling changed.  // Drug Topics;3/6/95, Vol. 139 Issue 5, p8 

    Reports on Roche Laboratories decision to change the labeling on its Toradol prescription pain reliever due to reports on side effects from improper use. Usage of the drug for pain management in postsurgical patients.

  • Program prevents pregnancies during tx.  // Dermatology Times;Sep95, Vol. 16 Issue 9, p3 

    Reports on the pregnancy prevention program conducted by Hoffman-La Roche Inc. during isotretinoin treatment for its patients.

  • La Roche lottery.  // Northern New Jersey Business;6/28/95, Vol. 3 Issue 13, p3 

    Reports on the US Food and Drug Administration's approval of the drug called Invirase, manufactured by Hoffman-La Roche.

  • Roche cuts controversial PCR fees, testing limits. Anderson, C. // Nature;1/30/1992, Vol. 355 Issue 6359, p379 

    Reports that Swiss-owned pharmaceutical company Hoffmann-La Roche, under pressure from researchers and diagnostic companies, agreed to lower its prices on its polymerase chain reaction (PCR) technology and lift restrictions on its use. The move should free the technology for widespread use in...

  • Licences sought from PCR users in Britain. Dickson, David // Nature;1/28/1993, Vol. 361 Issue 6410, p291 

    Reports that genetic-screening devices throughout Britain could have their costs increase significantly as a result of claims for royalties on one of the basic laboratory techniques used in diagnostic testing, polymerase chain reaction (PCR). Recent granting of two patents on the PCR process by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics